Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis

Journal of Allergy and Clinical Immunology

Volumn 111, Issue 3, 2003, Pages 617-622

  Simons, F Estelle R ^a,e   Prenner, Bruce M ^b,c   Finn Jr , Albert ^d  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c Allergy Associates Medical Group Inc   (United States)

^d Natl Allerg Asthma/Urticaria C   (United States)

^e NONE   (Canada)

Author keywords

Desloratadine; H1 antihistamine; Perennial allergic rhinitis; Persistent allergic rhinitis

Indexed keywords

DESLORATADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; PLACEBO;

ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; ANAPHYLAXIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; EVIDENCE BASED MEDICINE; FEMALE; HEADACHE; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCULAR PRURITUS; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCHOOL CHILD; SEASONAL VARIATION; SNEEZING; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT PLANNING; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; XEROSTOMIA;

EID: 0037338987     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2003.168     Document Type: Article

References (23)

1. Sibbald B, Rink E. Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history. Thorax 1991;46:895-901.
2. Bousquet J, van Cauwenberge PB, Khaltaev N, et al. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:1A-4A, S147-334.
3. Dykewicz MS, Fineman S. Diagnosis and management of rhinitis: parameter documents of the Joint Task Force on Practice Parameters in Allergy. Asthma, and Immunology. Ann Allergy Asthma Immunol 1998;81:463-518.
4. Christodoulopoulos P, Cameron L, Durham S, Hamid Q. Molecular pathology of allergic disease. II: Upper airway disease. J Allergy Clin Immunol 2000;105:211-23.
5. 1-antihistamines in allergic disease. 2nd Ed. New York: Marcel Dekker, Inc; 2002. p. 179-200.
6. 1 receptor antagonist: 1st communication: receptor selectivity, antihistaminic activity, and anti-allergenic effects. Arzneimittelforschung/Drug Res 2000;50:345-52.
7. Geha RS, Meltzer EO. Desloratadine: a new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001;107:752-62.
8. 1-receptor antagonist. Clin Pharmacokinet 2002;41(suppl 1):1-44.
9. 1-receptor antagonist, in patients with seasonal allergic rhinitis: assessment during the spring and fall allergy seasons. Clin Drug Invest 2001;21:25-32.
10. Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001;56:1077-80.
11. Bachert C. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy 2001;56(suppl 65):14-20.
12. Grossman J, Halverson PC, Meltzer EO, et al. Double-blind assessment of azelastine in the treatment of perennial allergic rhinitis. Ann Allergy 1994;73:141-6.
13. Mansmann HC Jr, Altman RA, Berman BA, et al. Efficacy and safety of cetirizine therapy in perennial allergic rhinitis. Ann Allergy 1992;68:348-53.
14. Murris-Espin M, Melac M, Charpentier JC, Didier A. Comparison of efficacy and safety of cetirizine and ebastine in patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol 1998;80:399-403.
15. Bousquet J, Duchateau J, Pignat JC, et al. Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire. J Allergy Clin Immunol 1996;98:309-16.
16. Picado Valles C, Cadahia Garcia A, Cistero Bahima A, Cano Cantudo L, Sanz Amaro A, Zayas Sanza JM. Ebastine in perennial allergic rhinitis. Ann Allergy 1991;67:615-8.
17. Bousquet J, Guadano EM, Palma Carlos AG, Staudinger H. A 12-week, placebo-controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis. Multicentre Study Group. Allergy 1999;54:562-8.
18. Ciprandi G, Cosentino C, Milanese M, Mondino C, Canonica GW. Fexofenadine reduces nasal congestion in perennial allergic rhinitis. Allergy 2001;56:1068-70.
19. Bruttmann G, Charpin D, Germouty J, Horak F, Kunkel G, Wittmann G. Evaluation of the efficacy and safety of loratadine in perennial allergic rhinitis. J Allergy Clin Immunol 1989;83:411-6.
20. Frolund L, Etholm B, Irander K, et al. A multicentre study of loratadine, clemastine and placebo in patients with perennial allergic rhinitis. Allergy 1990;45:254-61.
21. Bellioni P, Catalano B, Cervellera G, Filiaci F, Mira E, Carraro A, Comparison of mizolastine with loratadine in the treatment of perennial allergic rhinitis. Rhinology 1996;34:101-4.
22. Bachert C, Brostoff J, Scadding GK, Tasman J, Stalla-Bourdillon A, Murrieta M. Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis. RIPERAN Study Group. Allergy 1998;53:969-75.
23. Wilson A, Dempsey OJ, Sims EJ, Coutie WJ, Paterson MC, Lipworth BJ. Evaluation of treatment response in patients with seasonal allergic rhinitis using domiciliary nasal peak inspiratory flow. Clin Exp Allergy 2000;30:833-8.